Renal cell cancer: Highlights from ASCO 2020

Bookmark and Share
Published: 13 Jul 2020
Views: 484
Prof Scott Tykodi - University of Washington, Seattle, USA

Prof Scott Tykodi speaks to ecancer in an online interview for the virtual ASCO 2020 meeting.

He discusses his main renal cancer highlights from ASCO 2020, with reference to the KEYNOTE 426 and CheckMate 214 studies.

Prof Tykodi also outlines a phase II trial that investigated the use of bevacizumab and erlotinib in patients with advanced hereditary leiomyomatosis and renal cell cancer (HLRCC) or sporadic papillary renal cell cancer.